Farmacorecensioni
Montelukast
FEDERICO MARCHETTI
Divisione di Pediatria e Neonatologia, Ospedale Civile di Matera
Febbraio 1999 - pagg. 111 -112
Suggerite dall'AI
Classificazione MeSH
Bibliografia
Lavori di revisione
Holgate ST, Bradding P, Sampson A: Leukotriene
antagonists and synthesis inhibitors: new
directions in asthma therapy. J Allergy Clin Immunol
98, 1-13, 1996.
Coen D: Antileucotrieni nell’asma. Occhio Clinico
2, 30, 1998.
Sampson A: Leukotriene modifiers in the treatment
of asthma. BMJ 316, 1257-8, 1998.
Ravaioli F, Romero M: Antileucotrieni: una
nuova terapia per la sindrome asmatica?
Informazione sui Farmaci 22 (N° 2), 33-
39,1998.
Montelukast nell’asma persistente. The Medical
Letter (ed Italiana) 18, 87-88, 1998.
Lipworth BJ: Leukotriene-receptor antagonists.
Lancet 353, 57-62, 1999.
Studi clinici nel bambino
Knorr B, Matz J, Bernstein JA, et al: Montelukast
for chronic asthma in 6 to 14 year old
children. JAMA 279, 1181-86, 1998.
Kemp JP, Dockborn RJ, Shapiro GG, et al:
Montelukast once daily inhibits exercise-induced
bronchoconstriction in 6 to 14 year old
children with asthma. J Pediatr 133, 424-8,
1998.
Studi clinici nell’adulto
Leff JA, Israel E, Noonan MJ, et al: Montelukast
allows tapering of inhaled corticosteroids in
asthmatic patients while maintaining clinical
stability (abstract). Am J Respir Crit Care Med
155, A976, 1997.
Reiss TF, Chervinsky P, Dockhorn RJ, et al:
Montelukast, a once daily leukotriene receptor
antagonist, in the treatment of chronic asthma.
Arch Inter Med 158, 1213-20, 1998.
Leff JA, Busse WW, Pearlman D, et al: Montelukast,
a leukotriene receptor antagonist, for
the treatment of mild asthma and exercise induced
bronchoconstriction. N Engl J Med 339,
147-52, 1998.